Keimar

Keimar Therapeutics is a biotechnology company focused on developing novel small molecule therapies that target the Keap1-Nrf2 pathway. A spin-out from the University of Dundee and the University of Edinburgh, the company leverages deep expertise in the structural biology and pharmacology of the Keap1-Nrf2 protein-protein interaction. Their primary objective is to develop inhibitors that activate the Nrf2 antioxidant response to treat chronic inflammatory and degenerative diseases, including chronic kidney disease. By specifically targeting the Keap1-Nrf2 interface, Keimar aims to provide more precise and effective therapeutic options than traditional electrophilic Nrf2 activators.